AstraZeneca (AZN) and Daiichi Sankyo's Enhertu treatment showed a "statistically significant and clinically meaningful" improvement in overall survival, compared with ramucirumab plus paclitaxel in patients with second-line HER2 positive unresectable and/or metastatic gastric or gastroesophageal junction adenocarcinoma, Daiichi Sankyo said Saturday.

Based on the results from a phase 3 trial, Enhertu lowered the risk of death by 30% versus ramucirumab plus paclitaxel. Median overall survival was 14.7 months versus 11.4 months, according to the company.

In the secondary endpoint analysis of progression-free survival, Enhertu showed a 26% reduction in the risk of disease progression or death, compared with ramucirumab plus paclitaxel, Daiichi Sankyo said.